Logo image of KMDA

KAMADA LTD (KMDA) Stock Fundamental Analysis

NASDAQ:KMDA - Nasdaq - IL0010941198 - Common Stock - Currency: USD

6.9  +0.14 (+2.07%)

After market: 6.55 -0.35 (-5.07%)

Fundamental Rating

6

Overall KMDA gets a fundamental rating of 6 out of 10. We evaluated KMDA against 572 industry peers in the Biotechnology industry. KMDA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. KMDA is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make KMDA suitable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year KMDA was profitable.
KMDA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: KMDA reported negative net income in multiple years.
Of the past 5 years KMDA 4 years had a positive operating cash flow.
KMDA Yearly Net Income VS EBIT VS OCF VS FCFKMDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

1.2 Ratios

The Return On Assets of KMDA (4.47%) is better than 94.34% of its industry peers.
Looking at the Return On Equity, with a value of 6.16%, KMDA belongs to the top of the industry, outperforming 94.87% of the companies in the same industry.
KMDA has a Return On Invested Capital of 4.42%. This is amongst the best in the industry. KMDA outperforms 94.69% of its industry peers.
Industry RankSector Rank
ROA 4.47%
ROE 6.16%
ROIC 4.42%
ROA(3y)0.31%
ROA(5y)4.38%
ROE(3y)0.28%
ROE(5y)5.38%
ROIC(3y)N/A
ROIC(5y)N/A
KMDA Yearly ROA, ROE, ROICKMDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10

1.3 Margins

KMDA has a better Profit Margin (9.92%) than 95.04% of its industry peers.
KMDA's Profit Margin has declined in the last couple of years.
KMDA has a better Operating Margin (11.21%) than 95.04% of its industry peers.
In the last couple of years the Operating Margin of KMDA has declined.
KMDA's Gross Margin of 42.52% is fine compared to the rest of the industry. KMDA outperforms 76.99% of its industry peers.
In the last couple of years the Gross Margin of KMDA has remained more or less at the same level.
Industry RankSector Rank
OM 11.21%
PM (TTM) 9.92%
GM 42.52%
OM growth 3Y-21.17%
OM growth 5Y-15.97%
PM growth 3Y-23.21%
PM growth 5Y-21.48%
GM growth 3Y2.9%
GM growth 5Y1.44%
KMDA Yearly Profit, Operating, Gross MarginsKMDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30

More info and screens

7

2. Health

2.1 Basic Checks

KMDA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, KMDA has more shares outstanding
The number of shares outstanding for KMDA has been increased compared to 5 years ago.
KMDA has a better debt/assets ratio than last year.
KMDA Yearly Shares OutstandingKMDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
KMDA Yearly Total Debt VS Total AssetsKMDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 3.43 indicates that KMDA is not in any danger for bankruptcy at the moment.
The Altman-Z score of KMDA (3.43) is better than 76.28% of its industry peers.
KMDA has a debt to FCF ratio of 0.35. This is a very positive value and a sign of high solvency as it would only need 0.35 years to pay back of all of its debts.
KMDA has a Debt to FCF ratio of 0.35. This is amongst the best in the industry. KMDA outperforms 96.81% of its industry peers.
KMDA has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of KMDA (0.04) is worse than 60.35% of its industry peers.
Even though the debt/equity ratio score it not favorable for KMDA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.35
Altman-Z 3.43
ROIC/WACC0.49
WACC9.02%
KMDA Yearly LT Debt VS Equity VS FCFKMDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 4.84 indicates that KMDA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.84, KMDA is in line with its industry, outperforming 52.57% of the companies in the same industry.
KMDA has a Quick Ratio of 2.73. This indicates that KMDA is financially healthy and has no problem in meeting its short term obligations.
KMDA has a Quick ratio of 2.73. This is in the lower half of the industry: KMDA underperforms 67.43% of its industry peers.
Industry RankSector Rank
Current Ratio 4.84
Quick Ratio 2.73
KMDA Yearly Current Assets VS Current LiabilitesKMDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 115.38% over the past year.
Measured over the past years, KMDA shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -22.88% on average per year.
The Revenue has been growing slightly by 4.53% in the past year.
KMDA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.48% yearly.
EPS 1Y (TTM)115.38%
EPS 3Y-27.28%
EPS 5Y-22.88%
EPS Q2Q%16.67%
Revenue 1Y (TTM)4.53%
Revenue growth 3Y2.28%
Revenue growth 5Y4.48%
Sales Q2Q%10.03%

3.2 Future

Based on estimates for the next years, KMDA will show a very strong growth in Earnings Per Share. The EPS will grow by 35.19% on average per year.
Based on estimates for the next years, KMDA will show a quite strong growth in Revenue. The Revenue will grow by 10.37% on average per year.
EPS Next Y65.46%
EPS Next 2Y53.54%
EPS Next 3Y35.19%
EPS Next 5YN/A
Revenue Next Year12.09%
Revenue Next 2Y10.32%
Revenue Next 3Y10.37%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
KMDA Yearly Revenue VS EstimatesKMDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
KMDA Yearly EPS VS EstimatesKMDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 -0.2 0.4 -0.4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

KMDA is valuated rather expensively with a Price/Earnings ratio of 24.64.
KMDA's Price/Earnings ratio is rather cheap when compared to the industry. KMDA is cheaper than 95.04% of the companies in the same industry.
When comparing the Price/Earnings ratio of KMDA to the average of the S&P500 Index (28.47), we can say KMDA is valued inline with the index average.
The Price/Forward Earnings ratio is 19.51, which indicates a rather expensive current valuation of KMDA.
Based on the Price/Forward Earnings ratio, KMDA is valued cheaply inside the industry as 94.87% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 92.74, KMDA is valued rather cheaply.
Industry RankSector Rank
PE 24.64
Fwd PE 19.51
KMDA Price Earnings VS Forward Price EarningsKMDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

KMDA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. KMDA is cheaper than 97.17% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, KMDA is valued cheaply inside the industry as 97.70% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 12.46
EV/EBITDA 10.95
KMDA Per share dataKMDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

KMDA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
KMDA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as KMDA's earnings are expected to grow with 35.19% in the coming years.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y53.54%
EPS Next 3Y35.19%

More info and screens

0

5. Dividend

5.1 Amount

KMDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KAMADA LTD

NASDAQ:KMDA (2/4/2025, 8:00:02 PM)

After market: 6.55 -0.35 (-5.07%)

6.9

+0.14 (+2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)02-12 2025-02-12/amc
Inst Owners12.01%
Inst Owner Change-3.56%
Ins Owners2.34%
Ins Owner ChangeN/A
Market Cap396.68M
Analysts85
Price Target14.96 (116.81%)
Short Float %0.14%
Short Ratio0.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.67%
Min EPS beat(2)2.94%
Max EPS beat(2)38.4%
EPS beat(4)3
Avg EPS beat(4)20.79%
Min EPS beat(4)-34.64%
Max EPS beat(4)76.47%
EPS beat(8)6
Avg EPS beat(8)3.01%
EPS beat(12)7
Avg EPS beat(12)-116.13%
EPS beat(16)7
Avg EPS beat(16)-106.96%
Revenue beat(2)1
Avg Revenue beat(2)2.45%
Min Revenue beat(2)0%
Max Revenue beat(2)4.89%
Revenue beat(4)1
Avg Revenue beat(4)-0.76%
Min Revenue beat(4)-5.28%
Max Revenue beat(4)4.89%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)1.57%
Revenue beat(16)4
Avg Revenue beat(16)-1.06%
PT rev (1m)-5.38%
PT rev (3m)4.76%
EPS NQ rev (1m)-11.12%
EPS NQ rev (3m)18.51%
EPS NY rev (1m)2.81%
EPS NY rev (3m)-5.2%
Revenue NQ rev (1m)-1.8%
Revenue NQ rev (3m)-2.91%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)0.45%
Valuation
Industry RankSector Rank
PE 24.64
Fwd PE 19.51
P/S 2.5
P/FCF 12.46
P/OCF 9.53
P/B 1.55
P/tB 1.55
EV/EBITDA 10.95
EPS(TTM)0.28
EY4.06%
EPS(NY)0.35
Fwd EY5.12%
FCF(TTM)0.55
FCFY8.02%
OCF(TTM)0.72
OCFY10.49%
SpS2.75
BVpS4.44
TBVpS4.44
PEG (NY)0.38
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.47%
ROE 6.16%
ROCE 5.6%
ROIC 4.42%
ROICexc 5.72%
ROICexgc 5.72%
OM 11.21%
PM (TTM) 9.92%
GM 42.52%
FCFM 20.09%
ROA(3y)0.31%
ROA(5y)4.38%
ROE(3y)0.28%
ROE(5y)5.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-29.01%
ROICexcg growth 5Y-21.23%
ROICexc growth 3Y-45.67%
ROICexc growth 5Y-33.16%
OM growth 3Y-21.17%
OM growth 5Y-15.97%
PM growth 3Y-23.21%
PM growth 5Y-21.48%
GM growth 3Y2.9%
GM growth 5Y1.44%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.35
Debt/EBITDA 0.31
Cap/Depr 75.79%
Cap/Sales 6.18%
Interest Coverage 35.36
Cash Conversion 135.71%
Profit Quality 202.55%
Current Ratio 4.84
Quick Ratio 2.73
Altman-Z 3.43
F-Score7
WACC9.02%
ROIC/WACC0.49
Cap/Depr(3y)47.86%
Cap/Depr(5y)61.3%
Cap/Sales(3y)3.54%
Cap/Sales(5y)3.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)115.38%
EPS 3Y-27.28%
EPS 5Y-22.88%
EPS Q2Q%16.67%
EPS Next Y65.46%
EPS Next 2Y53.54%
EPS Next 3Y35.19%
EPS Next 5YN/A
Revenue 1Y (TTM)4.53%
Revenue growth 3Y2.28%
Revenue growth 5Y4.48%
Sales Q2Q%10.03%
Revenue Next Year12.09%
Revenue Next 2Y10.32%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y56.93%
EBIT growth 3Y-19.37%
EBIT growth 5Y-12.21%
EBIT Next Year208.79%
EBIT Next 3Y57.23%
EBIT Next 5YN/A
FCF growth 1Y138.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y146.66%
OCF growth 3Y-39.11%
OCF growth 5Y-16.37%